Onabotulinumtoxin-A in Chronic Migraine: Should Timing and Definition of Non-Responder Status Be Revised? Suggestions From a Real-Life Italian Multicenter Experience

Migraine and Headache

Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study

Headache

Barbanti P, Aurilia C, Egeo G, Fofi L, Cevoli S, Colombo B, Filippi M, Frediani F, Bono F, Grazzi L, Salerno A, Mercuri B, Carnevale A, Altamura C, Vernieri F

doi: 10.1111/head.14032

Migraine and Headache

Optimizing the long-term management of chronic migraine with onabotulinumtoxinA in real life

Expert Rev Neurother.

Tassorelli C, Tedeschi G, Sarchielli P, Pini LA, Grazzi L, Geppetti P, De Tommaso M, Aguggia M, Cortelli P, Martelletti P

doi: 10.1080/

RECOMMENDED

Migraine and Headache

A Real-World Analysis of Patient Characteristics, Treatment Patterns, and Level of Impairment in Patients With Migraine Who are Insufficient Responders vs Responders to Acute Treatment

★ 2 Recommended by Prof. Dr Claudio Gobbi, Faculty Member

Headache.

Lombard L, Ye W, Nichols R, Jackson J, Cotton S, Joshi S

doi: 10.1111/head.13835.

Migraine and Headache

Living with chronic migraine: a qualitative study on female patients' perspectives from a specialised headache clinic in Spain

BMJ Open.

Palacios-Ceña D, Neira-Martín B, Silva-Hernández L, Mayo-Canalejo D, Florencio LL, Fernández-de-Las-Peñas C, García-Moreno H, García-Azorín D, Cuadrado ML

doi: 10.1136/

Migraine and Headache

A prospective real-world analysis of OnabotulinumtoxinA in chronic migraine post-NICE U.K. technology appraisal

Eur J Neurol.

Andreou AP, Trimboli M, Al-Kaisy A, Murphy M, Palmisani S, Fenech C, Smith T, Lambru G

doi: 10.1111/ene.13657.

Migraine and Headache

CGRP and PTX3 as Predictors of Efficacy of Onabotulinumtoxin Type A in Chronic Migraine: An Observational Study

Headache.

Domínguez C, Vieites-Prado A, Pérez-Mato M, Sobrino T, Rodríguez-Osorio X, López A, Campos F, Martínez F, Castillo J, Leira R

doi: 10.1111/head.13211.

Migraine and Headache

Discontinuation of Acute Prescription Medication for Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study

Headache.

Lipton RB, Hutchinson S, Ailani J, Reed ML, Fanning KM, Manack Adams A, Buse DC

doi: 10.1111/head.13642.

Migraine and Headache

Association Between Personality Traits and Onabotulinumtoxin A Response in Patients With Chronic Migraine

Headache.

Gonzalez-Martinez A, Rodríguez Vázquez E, de la Red Gallego H, García-Azorín D, Gallego de La Sacristana M, Guerrero Peral ÁL, Gago-Veiga AB

doi: 10.1111/head.13693.

Migraine and Headache

Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine-preventive medications in the phase 3b FOCUS study

Headache

Spierings ELH, Ning X, Ramirez Campos V, Cohen JM, Barash S, Buse DC

doi: 10.1111/head.14196

Related content

Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study

Optimizing the long-term management of chronic migraine with onabotulinumtoxinA in real life

A Real-World Analysis of Patient Characteristics, Treatment Patterns, and Level of Impairment in Patients With Migraine Who are Insufficient Responders vs Responders to Acute Treatment

Living with chronic migraine: a qualitative study on female patients' perspectives from a specialised headache clinic in Spain

A prospective real-world analysis of OnabotulinumtoxinA in chronic migraine post-NICE U.K. technology appraisal

CGRP and PTX3 as Predictors of Efficacy of Onabotulinumtoxin Type A in Chronic Migraine: An Observational Study

Discontinuation of Acute Prescription Medication for Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study

Association Between Personality Traits and Onabotulinumtoxin A Response in Patients With Chronic Migraine

Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine-preventive medications in the phase 3b FOCUS study